Protalix BioTherapeutics (PLX) Tops Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.35 +2.17%
Revenue Growth %: -49.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -49.8%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.07), $0.08 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.7 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- RenaissanceRe Holdings (RNR) PT Raised to $315 at TD Cowen
- DigitalOcean projects record Q2 2026 results with RPO above $800M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
